Cited 0 times in
Poziotinib for HER2-positive metastatic breast cancer (MBC): Final clinical efficacy and safety results for long-term follow-up of the phase II NOV120101-203 trial
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2023-06-02T01:06:30Z | - |
dc.date.available | 2023-06-02T01:06:30Z | - |
dc.date.issued | 2022-05 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194660 | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Poziotinib for HER2-positive metastatic breast cancer (MBC): Final clinical efficacy and safety results for long-term follow-up of the phase II NOV120101-203 trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Y.H. Park | - |
dc.contributor.googleauthor | K.H. Jung | - |
dc.contributor.googleauthor | J. Sohn | - |
dc.contributor.googleauthor | K.S. Lee | - |
dc.contributor.googleauthor | J.H. Kim | - |
dc.contributor.googleauthor | Y. Yang | - |
dc.contributor.googleauthor | E. Baek | - |
dc.contributor.googleauthor | H. Han | - |
dc.contributor.googleauthor | S-A. Im | - |
dc.identifier.doi | 10.1016/j.annonc.2022.03.195 | - |
dc.relation.journalcode | J00171 | - |
dc.identifier.eissn | 1569-8041 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0923753422005749 | - |
dc.citation.volume | 33 | - |
dc.citation.number | Supplement 3 | - |
dc.citation.startPage | S207 | - |
dc.citation.endPage | S208 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, Vol.33(Supplement 3) : S207-S208, 2022-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.